This research identifies MCAM as a pivotal regulator of chemoresistance in SCLC via SOX2/MRP1/PI3K/AKT and metabolic reprogramming, presenting a compelling case for its therapeutic targeting. Here, MCAM is linked to small cell lung carcinoma.